Allergan, Inc. – Company Information

Actavis acquired Allergan, Inc. on November 17, 2014 for $66 billion. 

Allergan, Inc., is an American multinational pharmaceutical company that focuses on developing and marketing medical devices, pharmaceuticals, and over-the-counter consumer products.

It is based in Irvine, California.

The company was founded in 1950 by Gavin S. Herbert – a pharmacist who created the first antihistamine eye drop in the US.

Allergan now has a team of 10,500 employees and a presence in more than 100 countries. It operates manufacturing plants in Waco, Texas; San Jose, Costa Rica; Westport, Ireland; and Bridgewater, New Jersey.

Its leading products include: Botox® (onabotulinumtoxinA) for the treatment of overactive bladder with symptoms of urinary incontinence, Restasis® (cyclosporine ophthalmic emulsion) for chronic dry eye due to inflammation, Lumigan® (bimatoprost ophthalmic solution), Botox® Cosmetic (onabotulinumtoxinA) aesthetic medical treatment, and Juvéderm® dermal fillers.

In 2014, Valeant Pharmaceuticals International Inc. teamed up with Pershing Square Capital Management to make a hostile bid for the Botox maker.

Overview

Allergan Logo

  • Chairman and CEO: David E.I. Pyott
  • President: Douglas S. Ingram
  • Industry: Pharmaceutical
  • Type: Public company
  • Formed: 1948
  • Revenue: $7.237 billion USD (2014)
  • Net earnings: $1,528.8 million USD (2014)
  • Earnings per share: $5.12 USD (2014)
  • Company head office: 2525 Dupont Drive, Irvine, CA 92612-1599, USA
  • Employees: 10,500 (2014)
  • Website: http://www.allergan.com/
  • Investor relations number: (714) 246-4636
  • Investor relations email: [email protected]

Allergan, Inc., Financial Results, Years Ended December 31

Operating data (in $ millions)20142013
Product net sales$7,126.1$6,197.5
Total revenues$7,237.9$6,300.4
Cost of sales$842.4$795.8
Selling, general and administrative costs$2,837.2$2,519.4
Research and development$1,191.6$1,042.3
Operating income$2,009.3$1,809.3
Earnings from continuing operations$1,532.6$1,272.5
Net earnings$1,528.8$988.7
Net earnings attributable to Allergan, Inc.$1,524.2$985.1
Balance sheet data (in $ millions)
Total assets$12,415.7$10,574.3
Long-term debt$2,085.3$2,098.3
Total stockholders’ equity$7,753.0$6,463.2
Common share data (in $)
Basic earnings per share$5.12$3.32
Diluted earnings per share$5.01$3.26
Cash flow data (in $ millions)
Net cash provided by operating activities$1,927.8$1,695.4
Net cash used for investing activities$182.7$(1,375.3)
Net cash provided by (used for) financing activities$(204.0)$28.2
Cash and cash equivalents at beginning of year$3,046.1$2,701.8
Cash and cash equivalents at end of year$4,911.4$3,046.1

Financial Highlights Allergan

Source: “Allergan, Inc. Form 10-K 2014”